BONDED POWDERS FOR THE TREATMENT OF BODILY LESIONS
The present embodiments provide systems and medical formulations suitable for delivering therapeutic powders to a target site. In one embodiment, the system comprises a delivery device, a first powder being formed of particles of a first material, and a second powder being formed of particles of a second material, wherein the second material is different than the first material. At least some of the particles of the first powder and the second powder are bound together to form bonded particles. The bonded particles are simultaneously delivered to the target site by the delivery device. In one embodiment, a medical formulation may comprise carbomer present in a range between about 60-80% by weight of the formulation, bentonite present in a range of between about 5-15% by weight of the formulation, and calcium carbonate present in a range of between about 10-30% by weight of the formulation.
1 - 20 . (canceled)
21 . A medical formulation for protecting or treating a lesion, comprising:
a first powder being formed of particles of a first material, wherein the first powder comprises a mucoadhesive agent;
a second powder being formed of particles of a second material, wherein the second powder comprises a hemostatic agent,
wherein the particles of the first powder and the second powder are bound together to form bonded particles, and wherein the mucoadhesive agent is present in a greater quantity by weight of the formulation than the hemostatic agent,
wherein the mucoadhesive agent comprises carbomer and the hemostatic agent comprises bentonite;
the medical formulation further comprising calcium carbonate,
wherein the carbomer is present in a range between about 60-80% by weight of the formulation, the bentonite is present in a range of between about 5-15% by weight of the formulation, and the calcium carbonate is present in a range of between about 10-30% by weight of the formulation.
22 . The medical formulation of claim 21 , wherein at least 10% of the particles of the first powder and the second powder are bound together.
23 . The medical formulation of claim 21 , wherein the bonded particles of the first and second powders have a minimum width of at least 40 microns.
24 . The medical formulation of claim 21 , wherein the bonded particles of the first and second powders have a maximum width of less than 200 microns.
25 . The medical formulation of claim 21 , wherein a mass of the bonded particles is in a range of between about 0.0015 mg to about 0.15 mg per particle.
26 . The medical formulation of claim 21 , wherein a difference between a density of the particles of the first powder and a density of the particles of the second powder is at least two times.
27 . A medical formulation for protecting or treating a lesion, comprising:
a first powder being formed of particles of a first material, wherein the first powder comprises a mucoadhesive agent;
a second powder being formed of particles of a second material, wherein the second powder comprises a hemostatic agent,
wherein the particles of the first powder and the second powder are bound together to form bonded particles, wherein the bonded particles are filtered to a specific particle range size before being placed into a delivery device,
wherein the mucoadhesive agent is present in a greater quantity by weight of the formulation than the hemostatic agent,
wherein the mucoadhesive agent is present in a quantity of at least 50% by weight of the formulation, and
wherein the medical formulation further comprising calcium carbonate.
28 . The medical formulation of claim 27 , wherein the mucoadhesive agent comprises carbomer and the hemostatic agent comprises bentonite.
29 . The medical formulation of claim 29 , wherein the carbomer is present in a range between about 60-80% by weight of the formulation, the bentonite is present in a range of between about 5-15% by weight of the formulation, and the calcium carbonate is present in a range of between about 10-30% by weight of the formulation.
30 . The medical formulation of claim 27 , wherein at least 10% of the particles of the first powder and the second powder are bound together.
31 . The medical formulation of claim 27 , wherein the bonded particles of the first and second powders have a minimum width of at least 40 microns.
32 . The medical formulation of claim 27 , wherein the bonded particles of the first and second powders have a maximum width of less than 200 microns.
33 . The medical formulation of claim 27 , wherein a mass of the bonded particles is in a range of between about 0.0015 mg to about 0.15 mg per particle.
34 . The medical formulation of claim 27 , wherein the particles of the first powder and the second powder are bound together by one of hydrogen bonding, van der Waals bonding, metallic bonding, ionic bonding, covalent bonding, chain entanglement, coating, impaction or embedding.
35 . A medical formulation for protecting or treating a lesion, comprising:
a first powder being formed of particles of a first material, wherein the first powder comprises a mucoadhesive agent; and
a second powder being formed of particles of a second material, wherein the second powder comprises a hemostatic agent,
wherein the particles of the first powder and the second powder are bound together to form bonded particles,
wherein the mucoadhesive agent is present in a greater quantity by weight of the formulation than the hemostatic agent,
wherein the bonded particles of the first and second powders have a minimum width of at least 40 microns, and
wherein the bonded particles of the first and second powders have a maximum width of less than 200 microns.
36 . The medical formulation of claim 35 , wherein the mucoadhesive agent is present in a quantity of at least 50% by weight of the formulation.
37 . The medical formulation of claim 35 , wherein the mucoadhesive agent comprises carbomer and the hemostatic agent comprises bentonite.
38 . The medical formulation of claim 37 , further comprising calcium carbonate, wherein the carbomer is present in a range between about 60-80% by weight of the formulation, the bentonite is present in a range of between about 5-15% by weight of the formulation, and the calcium carbonate is present in a range of between about 10-30% by weight of the formulation.
39 . The medical formulation of claim 35 , wherein at least 10% of the particles of the first powder and the second powder are bound together.
40 . The medical formulation of claim 35 , wherein a mass of the bonded particles is in a range of between about 0.0015 mg to about 0.15 mg per particle.